Cue Biopharma Statistics
Total Valuation
Cue Biopharma has a market cap or net worth of $47.48 million. The enterprise value is $40.55 million.
Important Dates
The last earnings date was Monday, May 12, 2025, after market close.
| Earnings Date | May 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Cue Biopharma has 75.35 million shares outstanding. The number of shares has increased by 33.15% in one year.
| Current Share Class | 75.35M |
| Shares Outstanding | 75.35M |
| Shares Change (YoY) | +33.15% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 0.35% |
| Owned by Institutions (%) | 16.63% |
| Float | 75.08M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.85 |
| Forward PS | 8.83 |
| PB Ratio | 5.82 |
| P/TBV Ratio | 7.21 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 5.07 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.03, with a Debt / Equity ratio of 1.08.
| Current Ratio | 1.03 |
| Quick Ratio | 0.91 |
| Debt / Equity | 1.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -60.36 |
Financial Efficiency
Return on equity (ROE) is -221.66% and return on invested capital (ROIC) is -90.82%.
| Return on Equity (ROE) | -221.66% |
| Return on Assets (ROA) | -67.62% |
| Return on Invested Capital (ROIC) | -90.82% |
| Return on Capital Employed (ROCE) | -610.18% |
| Revenue Per Employee | $194,902 |
| Profits Per Employee | -$989,854 |
| Employee Count | 41 |
| Asset Turnover | 0.21 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -59.61% in the last 52 weeks. The beta is 1.42, so Cue Biopharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.42 |
| 52-Week Price Change | -59.61% |
| 50-Day Moving Average | 0.74 |
| 200-Day Moving Average | 1.04 |
| Relative Strength Index (RSI) | 39.10 |
| Average Volume (20 Days) | 169,437 |
Short Selling Information
The latest short interest is 892,678, so 1.18% of the outstanding shares have been sold short.
| Short Interest | 892,678 |
| Short Previous Month | 867,049 |
| Short % of Shares Out | 1.18% |
| Short % of Float | 1.19% |
| Short Ratio (days to cover) | 5.81 |
Income Statement
In the last 12 months, Cue Biopharma had revenue of $7.99 million and -$40.58 million in losses. Loss per share was -$0.65.
| Revenue | 7.99M |
| Gross Profit | -26.65M |
| Operating Income | -41.22M |
| Pretax Income | -49.97M |
| Net Income | -40.58M |
| EBITDA | -40.83M |
| EBIT | -41.22M |
| Loss Per Share | -$0.65 |
Full Income StatementBalance Sheet
The company has $14.05 million in cash and $7.13 million in debt, giving a net cash position of $6.92 million or $0.09 per share.
| Cash & Cash Equivalents | 14.05M |
| Total Debt | 7.13M |
| Net Cash | 6.92M |
| Net Cash Per Share | $0.09 |
| Equity (Book Value) | 6.58M |
| Book Value Per Share | 0.11 |
| Working Capital | 433,000 |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$34.72 million and capital expenditures -$161,000, giving a free cash flow of -$34.88 million.
| Operating Cash Flow | -34.72M |
| Capital Expenditures | -161,000 |
| Free Cash Flow | -34.88M |
| FCF Per Share | -$0.46 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -515.88% |
| Pretax Margin | -507.87% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Cue Biopharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -33.15% |
| Shareholder Yield | -33.15% |
| Earnings Yield | -85.49% |
| FCF Yield | -73.47% |
Analyst Forecast
The average price target for Cue Biopharma is $3.00, which is 376.12% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $3.00 |
| Price Target Difference | 376.12% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | -1.08% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Cue Biopharma has an Altman Z-Score of -25.42 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -25.42 |
| Piotroski F-Score | 3 |